Recombinant Human LILRB1/CD85j protein (rFc Tag)(HPLC verified)
种属
Human
纯度
>90 %, SDS-PAGE
>90%, SEC-HPLC
标签
rFc Tag
生物活性
未测试
验证数据展示
产品信息
纯度 | >90 %, SDS-PAGE >90%, SEC-HPLC |
内毒素 | <0.1 EU/μg protein, LAL method |
生物活性 |
Not tested |
来源 | HEK293-derived Human LILRB1 protein Gly24-His458 (Accession# Q8NHL6) with a rabbit IgG Fc tag at the C-terminus. |
基因ID | 10859 |
蛋白编号 | Q8NHL6 |
预测分子量 | 73.5 kDa |
SDS-PAGE | 80-100 kDa, reducing (R) conditions |
组分 | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
复溶 | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
储存条件 |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
运输条件 | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
背景信息
LILRB1 (Leukocyte Immunoglobulin-like Receptor B1), also known as CD85j, ILT, and MIR7, is a member of the immunoglobulin superfamily and is expressed in a wide variety of immune cells, including natural killer (NK) cells, monocytes, macrophages, and dendritic cells. LILRB1 acts as an immunosuppressive receptor functions and is involved in immunomodulation and regulation of immune response. Recently, HLA class I expression was shown to protect cancer cells from macrophage phagocytosis by interacting with LILRB1, making LILRB1 also a phagocytic checkpoint. LILRB1 is also a promising therapeutic target for patients with multiple myeloma.
参考文献:
1. Zeller T, et al. (2023). Front Immunol. 14:1240275. 2. Hu Z, et al. (2024). Front Immunol. 15:1421092. 3. Xian M, et al. (2024). Nat Commun. 15(1):5767.